BioCentury
ARTICLE | Clinical News

ImmunoMet starts Phase I of IM156 for solid tumors

November 3, 2017 4:50 AM UTC

ImmunoMet Therapeutics Inc. (Houston, Texas) began a Phase I trial of IM156 to treat solid tumors in up to 36 patients. The primary endpoint is to determine the maximum tolerated dose (MTD) and recommended Phase II dose. Secondary endpoints include preliminary tumor response and pharmacokinetics.

IM156 is a biguanide derivative that inhibits mitochondrial oxidative phosphorylation complex I (OXPHOS complex I)...